Innovative CRO Explorer

Founded in 2010 and based in Beijing, China, Innovative CRO Explorer is a biotech company that provides early drug discovery services from target validation to pre-clinical candidate identification. It has aboratories and business centers in Beijing, Shanghai, Xuzhou and Guiyang. The chairman of the board, Yan Li graduated from the University of Ruhr Bochum, Germany, and is a member of Daxing District CPPCC. In 2014, the company was funded by Beijing SME Innovation Fund. In 2021, it was certified as a national high-tech enterprise and Zhongguancun High-tech Enterprise. As of 2023, Innovative CRO Explorer has 7,000 square meters of laboratories and more than 350 employees. The company's main business is integrated biological services, target validation and development, target types and screening, protein degradation platform, drug efficacy evaluation, etc. It can provide more than 100 ion channels, 800 kinases/enzymes, 100 GPCRs, and 40 nuclear receptors assays on the shelf with validation data and screening information. The products are used in the fields of oncology, immunology, cardiovascular, and central nervous system diseases. It has developed target-based panel screening platforms that can accomplish target identification and assay validation, compounds screening from hit to lead, to pre-clinical drug candidate selection. The company generates revenue by offering a full spectrum of drug discovery services, including target validation, lead optimization, and preclinical candidate selection.

1. Series B

   May 14, 2024

   Amount

   Undisclosed

   Investors

   Locked

2. Series B

   Aug 3, 2023

   Amount

   $14M

   Investors

   Locked

3. Series B

   Jan 19, 2023

   Amount

   Undisclosed

   Investors

   Locked

4. Series B

   Sep 26, 2022

   Amount

   $14M

   Investors

   Locked

5. Series A

   May 14, 2021

   Amount

   Undisclosed

   Investors

   Locked

6. Angel

   Apr 7, 2013

   Amount

   Undisclosed

   Investors

   Locked